Imprime PGG: Clinical Trials

13 trials of Imprime PGG, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 5 terminated, 1 withdrawn. 8 Phase 2, 6 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 28Completed 5, Terminated 2, Withdrawn 1
Phase 16Completed 3, Terminated 3
Phase 31Terminated 1

Follow Imprime PGG: new trials by email Literature Review of Imprime PGG trials Research Report on Imprime PGG

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
odetiglucan, CDX-1140 - Metastatic Pancreatic Adenocarcinoma
Phase 1TerminatedHiberCell, Inc.52022-12-152024-04-10
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)
Imprime PGG, Pembrolizumab - Malignant Neoplasm of Breast
Phase 2CompletedHiberCell, Inc.262021-11-092023-06-22
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
Imprime PGG, Pembrolizumab - Pathologic Stage III Cutaneous Melanoma AJCC v8
Phase 2WithdrawnHiberCell, Inc.2021-08-152021-11-05
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Regorafenib, Atezolizumab, Imprime PGG - Colorectal Cancer
Phase 1 / Phase 2TerminatedHoffmann-La Roche962018-09-272023-11-07
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Imprime PGG, Pembrolizumab - Squamous Cell Carcinoma of the Head and Neck
Phase 2TerminatedHiberCell, Inc.12017-11-082018-12-14
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Imprime PGG, MK-3475 - Non-Small Cell Lung Cancer
Phase 1 / Phase 2CompletedLawrence Feldman, MD352017-07-112026-01-20
Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Imprime PGG, Pembrolizumab - Advanced Melanoma, Triple-Negative Breast Cancer
Phase 2CompletedHiberCell, Inc.642017-02-222024-07-09
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
Imprime PGG, Rituximab - Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Phase 2CompletedDana-Farber Cancer Institute252014-12-012026-04-06
(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
BTH1704, IMPRIME PGG, Gemcitabine - Pancreatic Cancer
Phase 1TerminatedUniversity of Illinois at Chicago32014-08-012015-05-01
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Imprime PGG + cetuximab, Cetuximab - Colorectal Cancer
Phase 3TerminatedHiberCell, Inc.2172011-04-012017-07-13
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
alemtuzumab, rituximab, PGG beta-glucan - B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Phase 1 / Phase 2CompletedMayo Clinic222011-01-012020-06-23
Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer
Imprime PGG - Colorectal Cancer
CompletedHiberCell, Inc.182009-06-012012-02-15
Phase Ia Dose-Escalation Safety, Pharmacodynamic and Pharmacokinetic Study of Imprime PGG™ Injection
Imprime PGG - Healthy
Phase 1CompletedHiberCell, Inc.242005-12-012007-10-11

Conditions studied

Colorectal Neoplasms (3)  ·  Recurrence (3)  ·  Anophthalmia with pulmonary hypoplasia (1)  ·  Breast Neoplasms (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)  ·  Pancreatic Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

HiberCell, Inc. (8)  ·  Dana-Farber Cancer Institute (1)  ·  Hoffmann-La Roche (1)  ·  Lawrence Feldman, MD (1)  ·  Mayo Clinic (1)  ·  University of Illinois at Chicago (1)

Countries

United States (12)  ·  France (2)  ·  Australia (1)  ·  Germany (1)  ·  Puerto Rico (1)  ·  South Korea (1)  ·  Switzerland (1)

Top investigators

Alison Stopeck, MD (1)  ·  Caron Jacobson, MD (1)  ·  Jeremy D Graff, PhD (1)  ·  Lawrence Feldman, M.D. (1)  ·  Leonard Saltz, MD (1)  ·  Mark O'Hara (1)  ·  Neeta Venepalli, MD (1)  ·  Neil H. Segal, MD, PhD (1)  ·  Neil Senzer, MD (1)  ·  Purvi Gada, MD (1)  ·  Steven Ansell, M.D. (1)

Results publications

PMID 39670007, PMID 40338159

NIH funding

2017 (1)